Abstract:
Methods and apparatus are disclosed for end-to-end ATM calls based on the interworking of ATM SVC signaling (such as private network-network interface signaling) with A.2630.1 AAL2 signaling. In one network, Q.2630.1 AAL2 signaling in the originating access segment triggers, on proper authentication, ATM SVC signaling (e.g., PNNI, IISP, AINI, etc.) in the core, which triggers Q.2630.1 AAL2 signaling in the terminating access segment. The triggering is done at the edge-core boundary where an AAL2 switch and/or multiplexer or an ATM switch with AAL2 multiplexing/switching capabilities is located. In the access network between the ATM-AAL2 edge switch and the edge gateway, multiplexed AAL2 virtual channel connections (VCCs) are typically used. Single-CID AAL2 SVCs are typically used in the core network, and between the ATM-AAL2 edge switch and PSTN trunk gateways. The binding of voice calls to ATM bearer channels is done at the edge gateway when triggered by a call agent.
Abstract:
This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.
Abstract:
This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.
Abstract:
Microparticles that include a bisphosphonate and a polymer are produced by a method that includes forming a water-in-oil emulsion by mixing an aqueous solution of the bisphosphonate with a combination of a biocompatible polymer and a polymer solvent. At least one aqueous liquid can be mixed with the water-in-oil emulsion to form a water-in-oil-in-water emulsion and to extract the polymer solvent from the polymer, thereby forming the microparticles. Methods of treating a patient in need of therapy include administering the microparticles described to the patient. In one embodiment, the microparticles are formulated for the sustained release of the bisphosphonate.
Abstract:
An inverse discrete-cosine transform apparatus that is simple in structure and can yet output pixel data items different in resolution. The apparatus comprises eight inverse discrete-cosine transform multipliers 23, ten field, compression, inverse discrete-cosine transform multipliers 22, eight selectors 24, eight selectors 25, eight buffers 26, eight sign multipliers 27, a control section, eight adders 28, and eight buffers 29. The control section controls the selectors 24, selectors 25, buffers 26 and sign multipliers 27 in accordance with whether the input discrete-cosine block has been subjected to field division and where the discrete-cosine coefficients are located in the block. One of the values input to the selectors 24, selectors 25, buffers 26 and sign multipliers 27 is thereby selected. The value selected is output after added with the plus sign or the minus sign. The adders 28 add the values output from the selectors 24, selectors 25, buffers 26 and sign multipliers 27. The buffers 29 store the values output from the adders 28.
Abstract:
The present invention relates to a process for the in situ preparation of optically pure (S)-3,4-dihydroxybutyric acid derivatives represented by the Formula [2] and more particularly, to a process which enables preparing optically pure (S)-3-hydroxy-&ggr;-butyrolactone represented by Formula [1] by oxidation of &agr;- or &bgr;-(1,4) linked disaccharide or oligosaccharide with an oxidant under basic condition to give acid and cyclization sequentially under acidic condition to give (S)-3-hydroxy-&ggr;-butyrolactone.
Abstract:
Openings are formed in a laminate of a polycrystalline silicon film and an LTO film on a channel layer. While the laminate is used as a mask, impurities are implanted into a place in the channel layer which is assigned to a source region. Also, impurities are implanted into another place in the channel layer which is assigned to a portion of a second gate region. A portion of the polycrystalline silicon film which extends from the related opening is thermally oxidated. The LTO film and the oxidated portion of the polycrystalline silicon film are removed. While a remaining portion of the polycrystalline silicon film is used as a mask, impurities are implanted into a place in the channel layer which is assigned to the second gate region. Accordingly, the source region and the second gate region are formed on a self-alignment basis which suppresses a variation in channel length.
Abstract:
A pulsed circuit topology including a pulsed domino flip-flop. A circuit includes a domino logic gate having a domino output node responsive to input data during an evaluate pulse. Reset circuitry initiates and self-terminates a reset pulse during which the domino output node is precharged. A latch responsive to a first pulsed clock input signal is provided to latch data indicated at the domino output node.
Abstract:
A novel process of lactonizaton in the preparation of statins (e.g., the HMG--CoA reductase inhibitors lovastatin and simvastatin) employs very mild reaction conditions. The improved process comprises dissolving the open ring hydroxy acid form of the statins in an organic solvent by heating at a temperature, which ranges from ambient to reflux of the solvent, under anhydrous conditions to produce a solution, treating the solution with a mild catalyst at a temperature from about ambient to 50.degree. C., and adding water to the solution to cause the statins in lactone form to crystalize from the reaction mixture. The mild catalyst used in the reaction is a salt of an organic base with an organic or inorganic acid, such as pyridine hydrobromide, pyridine hydrochloride, or pyridinium, p-toluene sulfonate. The organic solvent comprises a lower alkanol, a non-alcoholic polar solvent, or a mixture of the two.
Abstract:
A process for preparing simvastatin from lovastatin or mevinolinic acid in salt form comprises treating either starting material with cyclopropyl or butyl amine, the pyranone ring thereby being opened when lovastatin is the starting material, adding a methyl group to the 2-methylbutyrate side chain, and thereafter closing the open pyranone ring to produce simvastatin. The process is performed without protecting and deprotecting the two hydroxy groups of the open pyranone ring. In a preferred embodiment, the starting material is treated with cyclopropyl amine which produces simvastatin via the novel intermediate lovastatin cyclopropyl amide.